Article Information
History
- November 7, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Daniel K. Jin1,*,
- Daniel. J. Nesbitt1,*,
- Jenny Yang1,
- Haidee Chen1,
- Julie Horowitz3,
- Marcus Jones3,
- Rianna Vandergaast4,
- Timothy Carey4,
- Samantha Reiter4,
- Stephen J Russell5,4,7,
- Christos Kyratsous8,
- Andrea Hooper8,
- Jennifer Hamilton8,
- Manuel Ferreira3,
- Sarah Deng8,
- Donna Straus2,
- Aris Baras3,
- Christopher D. Hillyer1,2 and
- Larry L. Luchsinger1,#
- 1Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
- 2New York Blood Center Enterprises, New York, NY 10065, USA
- 3Regeneron Genetics Center, Tarrytown, NY 10591, USA
- 4Imanis Life Sciences, Rochester, MN 55901
- 5Vyriad, Inc., Rochester, MN 55901
- 7Mayo Clinic Department of Molecular Medicine, Rochester, MN 55905
- 8Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
- ↵#Address correspondence to Larry Luchsinger (Lead): lluchsinger{at}nybc.org.
↵* Authors contributed equally to this work.
Posted November 07, 2020.
Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”
